Amgen Inc. (AMGN) is currently trading at $366.05. Based on 29 Wall Street analysts, the average target price is $356.69, implying a 2.6% downside. The consensus recommendation is BUY.

AMGN

Amgen Inc.

HealthcareOpinion: buy

Opinion Criteria: Based on the consensus of Wall Street analysts. Strong Buy (1.0-1.5), Buy (1.5-2.5), Hold (2.5-3.5), Sell (3.5-4.5), Strong Sell (4.5-5.0).

Price (USD)

$366.05

Consensus target price range

Low–high band from analyst PT changes in the last 3 months; median & sample mean vs current price

LowHigh
$303.00$427.00
Current $366.05
Median: $340.00Mean: $352.30Current: $366.05

Recent price target updates (latest 80)

  • UBSJul 13, 2026

    PT action: Raises

    $400.00 → $420.00

  • GuggenheimJul 13, 2026

    PT action: Raises

    $340.00 → $343.00

  • Morgan StanleyJul 8, 2026

    PT action: Lowers

    $340.00 → $333.00

  • Truist SecuritiesJul 7, 2026

    PT action: Raises

    $327.00 → $340.00

  • Cantor FitzgeraldJul 6, 2026

    PT action: Maintains

    $350.00 → $350.00

  • MizuhoJun 16, 2026

    PT action: Raises

    $295.00 → $303.00

  • Morgan StanleyJun 10, 2026

    PT action: Raises

    $332.00 → $340.00

  • Piper SandlerMay 14, 2026

    PT action: Lowers

    $432.00 → $427.00

  • GuggenheimMay 4, 2026

    PT action: Lowers

    $351.00 → $340.00

  • Truist SecuritiesMay 1, 2026

    PT action: Raises

    $325.00 → $327.00

  • Canaccord GenuityApr 21, 2026

    PT action: Announces

    $0.00 → $366.00

  • UBSApr 13, 2026

    PT action: Raises

    $390.00 → $400.00

  • Morgan StanleyApr 10, 2026

    PT action: Raises

    $309.00 → $326.00

  • GuggenheimApr 9, 2026

    PT action: Raises

    $347.00 → $351.00

  • Cantor FitzgeraldApr 8, 2026

    PT action: Maintains

    $350.00 → $350.00

  • JefferiesMar 10, 2026

    PT action: Announces

    $0.00 → $350.00

  • BarclaysFeb 20, 2026

    PT action: Announces

    $0.00 → $350.00

  • Wells FargoFeb 19, 2026

    PT action: Raises

    $325.00 → $375.00

  • Piper SandlerFeb 18, 2026

    PT action: Raises

    $381.00 → $432.00

  • Freedom BrokerFeb 12, 2026

    PT action: Raises

    $360.00 → $375.00

Band uses only the revised target (Current column) from firm actions dated within the last 3 months—not the Prior price.

Avg Target

$356.69

Based on 29 analysts

Analyst Recommendations

Buy (14)Hold (17)Sell (3)

Upside

-2.56%

Market Cap

$197.56B

Financial & Investment Metrics

Next Earnings Date
Aug 4, 2026D-13
P/E Ratio (TTM)25.49
Forward P/E15.60
P/B Ratio21.50
Dividend Yield2.75%
Return on Equity (ROE)101.32%
Operating Margin33.80%
Debt to Equity623.75
Beta (Volatility)0.40
52 Week Range$269.77 - $391.29
LowCurrent: $366.05High

Latest News

Daily editorial mentioning AMGN

Price target moves

Healthcare and Tech Dominate as 24 Target Revisions Hit the Wire

The latest sentiment shift across the S&P 500 has been active, with 24 distinct ticker price targets adjusted over the last 14 days, according to data as of July 13, 2026. The activity is concentrated in the Healthcare and IT sectors, where institutional analysts are re-evaluating long-term valuation models despite recent price volatility.

Target changes

The moves reflect a mix of cautious recalibration and optimistic outlooks. UBS was particularly busy, issuing a series of upward revisions for healthcare heavyweights. Notably, the firm boosted LLY from 1250 to 1425 and VRTX from 545 to 585. Meanwhile, TD Cowen took a more selective approach, raising ADI to 460 from 450 while simultaneously lowering its outlook on ISRG twice in the same window—first to 600 and then to 520, signaling significant disagreement within the firm's own modeling trajectory.

Ticker Firm Dir Prior → Current
TSLA Jefferies Up 375 → 400
ISRG TD Cowen Down 585 → 520
FTNT TD Cowen Up 160 → 215
NFLX Oppenheimer Down 120 → 100

Industrial names also saw downward pressure, as TD Cowen trimmed its targets for both LMT and NOC, moving them to 560 and 580, respectively. In the communication services space, the outlook remains fragmented; while UBS lowered GOOGL to 400, the broader market volatility has left some price action feeling disconnected from recent fundamental adjustments.

How this differs from consensus

When we look at the spread between these new targets and the current consensus mean, it is clear that some analysts are leaning into extreme outcomes. For instance, the recent downgrade of NFLX to 100 by Oppenheimer sits at a striking variance compared to the broader market's expectations. This move suggests a fundamental questioning of subscriber growth narratives that the consensus has yet to fully internalize. Conversely, the aggressive upward revision for FTNT to 215 by TD Cowen highlights a divergence in how analysts account for cyber-security demand, placing the firm far ahead of the average valuation model. These target adjustments serve as a reminder that institutional consensus is often a lagging indicator, prone to rapid shifts when firm-level analysts pivot their core growth assumptions.

Read article

Insider Sentiment Index (Last 6 Months)

Counts and listings exclude stock awards, gifts, and option exercises—open-market purchases and sales only.

Buy vs Sell (Count)

Insider Buys: 0Insider Sells: 10

Whale Trades (C-Level Large Buys)

No major insider buying detected recently.

Recent Insider Transactions

DateNamePositionTransactionShares
5/4/2026GRYGIEL NANCY AOfficerSale at price 323.73 per share.1,237
2/26/2026SANTOS ESTEBANOfficerSale at price 379.12 per share.54,792
2/19/2026BUSCH MATTHEW C.OfficerSale at price 375.79 per share.1,000
11/20/2025GRYGIEL NANCY AOfficerSale at price 337.26 per share.3,139
11/12/2025GORDON MURDOOfficerSale at price 336.83 per share.6,879
11/12/2025KHOSLA RACHNAOfficerSale at price 336.24 per share.890
8/20/2025GRYGIEL NANCY AOfficerSale at price 296.98 per share.1,267
6/5/2025KHOSLA RACHNAOfficerSale at price 289.68 per share.1,500
5/2/2025BUSCH MATTHEW C.OfficerSale at price 279.69 per share.1,000
2/21/2025REESE DAVID M.Chief Technology OfficerSale at price 293.22 - 304.44 per share.33,936

Frequently Asked Questions

Q. What is the current target price and upside for AMGN?

A. The current target price for Amgen Inc. is $356.69, which implies a 2.6% downside from the current price of $366.05. This is based on the consensus of 29 Wall Street analysts.

Q. What is the current analyst recommendation for AMGN?

A. Currently, there are 4 Strong Buy, 10 Buy, 17 Hold, 2 Sell, and 1 Strong Sell ratings. The overall consensus is BUY.

Q. Are insiders buying AMGN stock recently?

A. Over the past 6 months, there have been 0 insider buys and 10 insider sells. Insider selling is more prominent recently.

Other Promising Stocks in Healthcare

Data provided by Yahoo Finance. This information is for informational purposes only and does not constitute investment advice. We bear no legal responsibility for any investment decisions made based on this data.

Read full disclaimer